$LRMR News

JP Morgan Initiates Coverage On Larimar Therapeutics with Overweight Rating, Announces Price Target of $9

Wedbush Maintains Outperform on Larimar Therapeutics, Lowers Price Target to $12

Larimar Therapeutics Q1 EPS $(0.31) Beats $(0.54) Estimate

Wedbush Raises its Price Target on Larimar Therapeutics (LRMR) to $13

Wedbush Maintains Outperform on Larimar Therapeutics, Raises Price Target to $13

Larimar: Q4 Earnings Snapshot

Larimar Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results

Larimar Therapeutics Q4 EPS $(0.73) Misses $(0.45) Estimate

Larimar Therapeutics to Participate in Upcoming Investor Conferences in March

Larimar Therapeutics price target raised to $12 from $11 at Wedbush

Wedbush Maintains Outperform on Larimar Therapeutics, Raises Price Target to $12

Larimar Therapeutics (LRMR) Is Up 78.8% After Breakthrough Nod And $100M Raise Has The Bull Case Changed?

Unusual volume stocks are being observed in Thursday's session.

Larimar Therapeutics shares are trading lower after the company announced that it priced its $100 million public offering of 20 million shares at $5.00 per share.

Larimar Therapeutics shares are trading lower after the company announced that it priced its $100 million public offering of 20 million shares at $5.00 per share.

Reported Earlier, Larimar Therapeutics Prices Upsized $100M Public Offering Of 20M Common Shares At $5.00 Each, To Fund Nomlabofusp Development

Larimar Therapeutics Announces Pricing of Upsized $100 Million Underwritten Public Offering

Larimar Therapeutics Announces Proposed $75 Million Underwritten Public Offering

Larimar Therapeutics Commences $75M Common Stock Offering

Laminar Therapeutics Stock Is Popping Today: What's Going On?